Patients with peritoneal metastasis from colorectal cancer have poor prognoses and are usually at advanced stage when first diagnosed. We have changed their treatment concepts for peritoneal metastasis of colorectal cancers from traditional palliative treatment to multidisciplinary treatments (including chemotherapy, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy). Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is introduced as a novel intraperitoneal administration approach to treat unresectable peritoneal metastasis from colorectal cancers. Compared with previous treatments, it has the advantages of minimal invasion, good safety, a homogeneous intraperitoneal distribution and enhanced tumour penetration. Owning to these advantages, PIPAC has been used in many countries around the world since its first application in humans in 2011. With increasingly improved technical models of PIPAC, several new treatment models were developed. The article reviews the history, technical criteria, complications, safety and prognosis of PIPAC treatment for peritoneal metastasis from colorectal cancers.